Inflammatory Bowel Disease Market: Current Analysis and Forecast (2024-2032)

Inflammatory Bowel Disease (IBD) is a chronic condition characterized by inflammation of the gastrointestinal tract. The two main types of IBD are Crohn's disease and ulcerative colitis. Both conditions cause severe symptoms such as abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. While the exact cause of IBD is unknown, it is believed to result from an interplay of genetic, environmental, and immune system factors. IBD can significantly impact a patient's quality of life and requires ongoing medical management, often including medication, lifestyle changes, and sometimes surgery. The IBD market is driven by the increasing prevalence of IBD, advancements in treatment options, and heightened awareness about the disease. For instance, as per the data of Crohn's & Colitis UK, about 1 in every 123 individuals is affected by either Crohn's disease or ulcerative colitis in the UK. This translates to nearly half a million people living with Inflammatory Bowel Disease (IBD) in the country. Although IBD is relatively uncommon, it still has a substantial impact on a significant number of people in the UK.

The Inflammatory Bowel Disease Market is expected to grow at a steady rate of around 5% rising prevalence of IBD, advancements in biologic therapies, and increased awareness and diagnosis. Further, new product launches are a critical driver of growth in the IBD treatment market. The introduction of advanced biologic therapies, biosimilars, innovative oral therapies, and a robust pipeline of emerging treatments are significantly enhancing the options available for managing IBD. These developments not only improve patient outcomes but also contribute to the substantial expansion of the market, offering promising opportunities for pharmaceutical companies and healthcare providers.

Based on the type, the market is segmented into Crohn's Disease and Ulcerative Colitis. In 2023, the Crohn's disease segment held a dominant market position, which is expected to persist during the forecast period. The segment is growing as a result of factors such the rising frequency of the ailment, the high expense of treating Crohn's disease, and the rise in the number of prescriptions for biologics. Moreover, the presence of strong pipeline candidates slated to launch in the coming years is expected to boost segment expansion. For example, the European Commission approved Skyrizi IV in November 2022 to treat moderate-to-severe Crohn's disease.

Based on the Drug Class, the market is segmented into Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, and Others. In 2022, the TNF inhibitors segment dominated the inflammatory bowel disease treatment market. This prominence is largely due to the increased prescription rates of TNF inhibitors for IBD and greater consumer awareness about these treatments. Key TNF inhibitors include Humira, Remicade, Simponi, Cimzia, and various biosimilars used to manage inflammatory conditions. However, the market growth may be challenged by the upcoming expiration of patents for these inhibitors.

Based on the distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. In 2022, the market for IBD treatments was controlled by the hospital pharmacy segment. The senior population's rise, high hospitalization rates, and the severity of IBD are predicted to fuel the segment's expansion. Furthermore, improved reimbursement policies covering expensive IBD treatment medicines in established and developing nations are anticipated to drive the segment's expansion. Conversely, the market for treatments for inflammatory bowel disease was dominated by the retail pharmacy sector, which had the second-largest share.

For a better understanding of the market adoption of Inflammatory Bowel Disease, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2023. This dominance can be attributed to several factors that drive the demand and development of IBD therapeutics in the region, such as high disposable income, advanced healthcare infrastructure, and rising awareness.

Some of the major players operating in the market include AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Eli Lilly and Company, UCB S.A., CELLTRION INC., Merck & Co., Inc., and Johnson & Johnson Services, Inc.